- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03615027
Dementia-specific Intervention of Advance Care Planning (ADIA)
This is a pilot study that aims to create a dementia-specific intervention of advance care planning (ACP) and test its feasibility and acceptance with min 20 max 30 patient-relative dyads.
The intervention is adapted from the Multiprofessional advance care planning and shared decision-making for end of life care (MAPS) Trials 1 and 2 made at the Zurich University Hospital.
The study design is longitudinal (historic): all the dyads will be asked to go through the process (4 visits, see 9.3 Procedures at each visit).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study background and aims:
Advance care planning (ACP) is a structured communication process between an individual, his family, and his healthcare agent (if existing), facilitated by a healthcare provider. The aim is to identify the personal values of the individual, reflect on the meanings and consequences of anticipated illness scenarios, define goals and preferences of care for these situations, issue appropriate documents and legal instruments that will help direct future healthcare decisions, and review these steps at adequate intervals. ACP emphasizes communication in anticipation of a future deterioration of a person's health. Even though dementia entails the loss of decision-making capacity, advance care planning is yet to become widespread. This study aims to close the gap and create a dementia-specific ACP intervention that:
- Support patient autonomy through advance care planning
- Improve participants' satisfaction and perceived control;
- Increase planning decisions and surrogate's knowledge of patients' preferences and values.
Procedure and measure:
Pre-intervention assessment (Visit 1):
If the patient and her/his relative have both consented to the study, the PI will ask the patient and her/his relative to fil out psychometric scales: Hospital anxiety and depression scale (HADS), Decisional conflict scale, Personal autonomy scale and Zarit Burden Inventory. Then, the PI will realize a semi-structured interview on patient's val-ues and treatment preferences and caregiver's knowledge of patient's preferences and care planning decisions that have already been made. Participants will also be asked to hand out a copy of any pre-existing advance directives or other advance care planning document.
Intervention (Visit 2):
In the intervention this first conversation (45-90 min) with a specifically trained ACP facilitator aims to explain the goal and content of ACP and prompt the patient to reflect upon his/her values and preferences for healthcare and discuss them with his/her caregiver. In addition, the written decision aids will be explained and provided to the patient/caregiver to be read at home. At the end of the meeting, the facilitator will ask to set up the second meeting.
Intervention (Visit 3):
The second conversation of the ACP facilitator with the patient and her/his caregiver aims to help the patient to specify her/his preferences and trans-late them into actionable documentation. The discussions also aim to empower the caregiver to make sure that these decisions are respected.
Post-intervention assessment (Visit 4):
The PI will start the meeting with a semi-structured interview (30-45 min) on the dyad's subjective experience with the intervention, positive and nega-tive effects, and challenges and suggestions to modify the intervention. Participants will also be asked to hand over copies of ACP documents produced during the intervention or after it in order to be analysed. After the interview, the PI will ask the patient and her/his relative to fill in psychometric scales: Hospital anxiety and depression scale (HADS), Decisional conflict scale, Personal autonomy scale and Zarit Burden Inventory.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Francesca Bosisio, PhD
- Phone Number: 0041 213141053
- Email: francesca.bosisio@chuv.ch
Study Contact Backup
- Name: Ralf J Jox, MD, PhD
- Phone Number: 0041 213145434
- Email: ralf.jox@chuv.ch
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1011
- Recruiting
- Lausanne University Hospital
-
Contact:
- Francesca Bosisio, PhD
- Phone Number: 0041 213141053
- Email: francesca.bosisio@chuv.ch
-
Contact:
- Ralf J Jox, MD, PhD
- Phone Number: 0041 213145434
- Email: ralf.jox@chuv.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 65 years
- Having been diagnosed with an early-stage dementia of Alzheimer's disease aetiology or mixed Alzheimer-vascular aetiology (Montreal cognitive assessement (MoCA) > 20 and Clinical dementia rating (CDR) < 1.5);
- Having been informed about the diagnosis by their treating physician and that are regularly followed by him/her;
- Patient that show interest in advance care planning or advance directives;
- Patients with psychiatric disorders can be included if their psychiatric symptoms are controlled and under the supervision of their psychiatrist at the Unit of psychogeriatric care;
- Retaining full decision-making capacity according to the MoCA > 20 or the clinical judgement a physician or psychologist. During the study, the PI and the facilitators will monitor patient's decision-making capacity clinically;
- Having the necessary French language competencies to engage in conversations;
- Having a close family caregiver over 18 years old, who is informed about the patient's diagnosis, possesses the before mentioned cognitive and communication skills, and is willingly to participate to this pilot intervention;
- Informed Consent for both members of the dyad as documented by signature;
Exclusion Criteria:
- Patients that have a dementia associated with fronto-temporal lobe degeneration;
- Patients that have mild cognitive impairments (MCI);
- Patients that have moderate to severe cognitive disorders, anosognosia or else, assessed clinically or through scales or based on in-person screening, that suggest decision-making capacity may be impaired;
- The patient or her/his caregiver decide to withdraw from the study;
- Enrolment of the investigator, his/her family members, employees and other dependent persons.
- Patients that have a dementia associated with fronto-temporal lobe degeneration;
- Patients that have MCI;
- Patients that have moderate to severe cognitive disorders, anosognosia or else, assessed clinically or through scales or based on in-person screening, that suggest decision-making capacity may be impaired;
- The patient or her/his caregiver decide to withdraw from the study;
- Enrolment of the investigator, his/her family members, employees and other dependent persons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
see detailed description
|
see detailed description
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in participants' anxiety and depression levels
Time Frame: Visit 1 and V4 (=V1 + 4-6 weeks)
|
Changes in participants' anxiety and depression levels measured with the Hospital Anxiety and Depression scale before (V1) and after (V4) the intervention.
The Hospital Anxiety and Depression Scale (HADS) allow the participant to assess her/his mood according to 24 items.
Individual's anxiety and depression levels are calculated by summing the score obtained at the eponym subscales, 0 being no anxiety or depression and 21 high anxiety or depression.
|
Visit 1 and V4 (=V1 + 4-6 weeks)
|
Change in participants' decisional conflict level
Time Frame: Visit 1 and V4 (=V1 + 4-6 weeks)
|
Changes in participants' decisional conflict levels measured with the Decisional conflict scale before (V1) and after (V4) the intervention.
The decisional conflict scale allow to participant to assess her/his ambivalence towards a specific treatment decision by choosing on a Lickert scale whether s/he strongly agrees (0 points), agrees (1 point), neither agrees nor disagrees (2 points), disagrees (3 points), or strongly disagrees (4 points) with a list of sentences.
Scores are then summed, divided by 16 and multiplied by 25.
Scores range from 0 (no decisional conflict) to 100 (extremely high decisional conflict).
|
Visit 1 and V4 (=V1 + 4-6 weeks)
|
Change in proxies' perception of the burden
Time Frame: Visit 1 and V4 (=V1 + 4-6 weeks)
|
Changes in relative's perceptions of the burden measured with the Zarit Burden Inventory before (V1) and after (V4) the intervention.
The Zarit Burden Inventory assesses relative's perceived burden of taking care of a sick and/or dependent loved one.
Relatives have to answer to indicate if they experienced 22 different situations or feelings never (1 point), rarely (2 points), sometimes (3 points), quite frequently (4 points), or nearly always (5 points).
Points at each item are summed: scores range from 22 (low perceived burden) to 110 (high perceived burden).
|
Visit 1 and V4 (=V1 + 4-6 weeks)
|
Changes in patients' psychological autonomy and perceived control
Time Frame: Visit 1 and V4 (=V1 + 4-6 weeks)
|
Changes in perceptions of patient's personal autonomy measured with the Psychological Autonomy Inventory before (V1) and after (V4) the intervention.
The Psychological Autonomy Inventory allows the patient to indicate on a scale from 1 to 5 (1 being never and 5 all the time) how s/he feels autonomous in different aspects of life.
Scores at the subscale of decisional control (items 3, 7, 10, 12, 14, 15, 16, 18, 19, 20, 25, 26, 27, and 28) are summed.
Items at the subscale of behavioral control (items 1, 2, 4, 5, 6, 8, 9, 11, 13, 17, 21, 22, 23, and 24) are summed.
A score of 14 means low decisional or behavioral control, a score of 70 means high decisional or behavioral control.
|
Visit 1 and V4 (=V1 + 4-6 weeks)
|
Participants' satisfaction with the intervention
Time Frame: Visit 1 and V4 (=V1 + 4-6 weeks)
|
Semi-structured interview at V4 explores dyad's experience with the intervention, whether advance decisions were documented during or after the intervention and how, and comments and suggestions to improve the intervention.
|
Visit 1 and V4 (=V1 + 4-6 weeks)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-00785
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Dementia-specific advance care planning
-
George Washington UniversityUniversity of Pittsburgh; Medstar Health Research Institute; Quality Insights; Renal... and other collaboratorsCompletedChronic Kidney DiseasesUnited States
-
Western Carolina UniversityPacific Institute for Research and EvaluationCompletedAdvance Care PlanningUnited States
-
University of PittsburghNational Cancer Institute (NCI)Active, not recruitingCancer | Advance Care PlanningUnited States
-
University of FloridaFlorida Department of HealthCompleted
-
Baystate Medical CenterPatient-Centered Outcomes Research Institute; University of New Mexico; Northeastern...Completed
-
Food and Health Bureau, Hong KongYan Chai HospitalCompleted
-
Oregon Health and Science UniversityUniversity of PennsylvaniaCompletedDementia | Advanced Care PlanningUnited States
-
McMaster UniversityCanadian Frailty NetworkCompletedChronic Disease | Frail Elderly SyndromeCanada
-
Food and Health Bureau, Hong KongCompletedChronic DiseaseHong Kong
-
Institut de cancérologie Strasbourg EuropeRecruiting